TGTX 14.31 Tg Therapeutics $TGTX Hit a 52 week high of

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 2:06 PM

TGTX 14.31 Tg Therapeutics $TGTX Hit a 52 week high of 14.57 Closing the day 09:44 at 14.31 +0.28 +2.00% With a day low of 13.93 and a total volume of 123,894.

TGTX Recent Posts: http://investorshangout.com/TG-Therapeutics-Inc-TGTX-64219/

TGTX Tg Therapeutics Recent Headline News

5 Momentum Stocks Currently on the Move with More Potential Upside
at The Street - 1 hr 32 mins ago
Achillion, Groupon, Orexigen, Rackspace and TG Therapeutics have had strong recent moves and are showing no sign of slowing.
OREX: 5.95 (+0.11), RAX: 43.74 (+1.14), ACHN: 13.72 (-1.13), TGTX: 14.41 (+0.38), GRPN: 7.80 (-0.30)

Nasdaq stocks posting largest percentage increases
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
ICUI: 83.85 (-0.88), OREX: 5.95 (+0.11), PCMI: 8.82 (+0.02), CYAN: 6.31 (+0.33), ACHN: 13.72 (-1.13), TGTX: 14.41 (+0.38), AGIO: 86.54 (-0.33), LIOX: 5.21 (-0.22), SAJA: 6.21 (+0.31), PLNR: 6.77 (-0.38)

TG Therapeutics' (TGTX) CEO Michael Weiss on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 2:03PM CST

TGTX: 14.41 (+0.38)

TG Therapeutics net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 11:10AM CST

TGTX: 14.41 (+0.38)

TG Therapeutics posts 3Q loss
Automated Insights - Tue Nov 11, 4:11AM CST
NEW YORK (AP) _ TG Therapeutics Inc. (TGTX) on Tuesday reported a loss of $17.5 million, or 51 cents per share, in its third quarter.
TGTX: 14.41 (+0.38)

TG Therapeutics misses by $0.19
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 4:12PM CST

TGTX: 14.41 (+0.38)

TG Therapeutics, Inc. Announces Third Quarter 2014 Financial Results and Business Update
GlobeNewswire - Mon Nov 10, 3:20PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for cancer and autoimmune diseases, today announced its results for the third quarter ended September 30, 2014 and recent company developments.
TGTX: 14.41 (+0.38)

TG Therapeutics reports November 11
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 3:10PM CST

TGTX: 14.41 (+0.38)

TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2014 Financial Results and Business Update
GlobeNewswire - Fri Nov 07, 3:00PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), announced today that a conference call will be held on Tuesday, November 11, 2014 at 8:30am ET to discuss results for the third quarter of 2014 and provide a business outlook for the remainder of the year. Michael Weiss, Executive Chairman and Interim Chief Executive Officer, will host the call.
TGTX: 14.41 (+0.38)

TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 56th American Society of Hematology Annual Meeting
GlobeNewswire - Thu Nov 06, 8:45AM CST
Combination of TG-1101, the Company's Novel Glycoenginereed Anti-CD20 Monoclonal Antibody and TGR-1202, the Company's Once Daily PI3K Delta Inhibitor to be Highlighted in Oral Presentation
TGTX: 14.41 (+0.38)

Strong On High Relative Volume: TG Therapeutics (TGTX)
at The Street - Mon Oct 27, 9:00AM CDT
Trade-Ideas LLC identified TG Therapeutics (TGTX) as a strong on high relative volume candidate
TGTX: 14.41 (+0.38)

Ligand Earns Milestone Payment on EU Approval of Noxafil - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 02, 12:00PM CDT
Ligand Pharmaceuticals Incorporated (LGND) earned a $550,000 milestone payment from partner Merck (MRK) on the EU approval of Noxafil (posaconazole) for infusion.
MRK: 59.37 (+0.06), TGTX: 14.41 (+0.38), LGND: 57.78 (+0.08), AMGN: 160.76 (-1.17)

TG Therapeutics reports exercise of its option to license the global rights to TGR-1202
M2 - Wed Sep 24, 6:17AM CDT
Biopharmaceutical company TG Therapeutics (NasdaqCM :TGTX) said on Tuesday that it has exercised its option to license the global rights to TGR-1202 from Rhizen Pharmaceuticals.
TGTX: 14.41 (+0.38)

Rhizen Pharmaceuticals Announces Out-licensing Agreement for TGR-1202, a Novel Next Generation PI3K-delta Inhibitor
GlobeNewswire - Tue Sep 23, 9:39AM CDT
Rhizen Pharmaceuticals S.A. today announced an out-licensing agreement for TGR-1202, a novel next generation PI3K-delta inhibitor. TG Therapeutics exercised its option for early conversion to a licensing agreement from a 50:50 joint venture partnership.
TGTX: 14.41 (+0.38)

TG Therapeutics Announces Exercise of License Option for Its Novel, Next Generation PI3K-Delta Inhibitor, TGR-1202
GlobeNewswire - Tue Sep 23, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that it has exercised its option to license the global rights to TGR-1202, the Company's novel, next generation PI3K-delta inhibitor from Rhizen Pharmaceuticals, S A ("Rhizen"

. The Company and Rhizen have to date been jointly developing TGR-1202 in a 50:50 joint venture. Given the successful development of TGR-1202, TG Therapeutics elected an early exercise of the Company's license option.
TGTX: 14.41 (+0.38)

TG Therapeutics (TGTX) in Focus: Stock Gains 16.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:46AM CDT
TG Therapeutics (TGTX) was a big mover last session, with shares rising over 16% on the day.
ICUI: 83.85 (-0.88), ABAX: 54.98 (+0.78), TGTX: 14.41 (+0.38), EGRX: 12.59 (-0.21)

TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA for Its First Phase 3 Clinical Trial of TG-1101 (ublituximab) in Combination With Imbruvica(R) (ibrutinib) for Patients With Previously Treated Chronic Lymphocytic Leukemia
GlobeNewswire - Mon Sep 15, 6:08AM CDT
Overall Response Rate (ORR) to be the Primary Endpoint to Support Accelerated Approval with Progression-Free Survival (PFS) to Support Full Approval
TGTX: 14.41 (+0.38)

UPDATE -- TG Therapeutics, Inc. to Present at the 16th Annual Rodman & Renshaw Global Investment Conference
GlobeNewswire - Mon Sep 08, 3:28PM CDT
In a release issued earlier today by TG Therapeutics, Inc. (Nasdaq:TGTX), please note the company's scheduled presentation time has changed to 1:15 PM ET, from 1:40 PM ET previously. The updated release follows:
TGTX: 14.41 (+0.38)

TG Therapeutics Inc. (TGTX) Stock Research Links

TGTX Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

EZRA Loop Fuses Human Insight and AI for Managers

Hybrid Coaching: The Future is Here If someone told me five years ago that human coaches and AI would team up to churn out better business leaders, I'd have a laugh. But here we are with EZRA Loop, an inventive mix of flesh-and-blood wisdom and algorithmic precision hitting the streets. This might seem like the latest buzzword pie in the sky to some, but there's a real...

GrOwnValve's Personalized Valves Pass Safety Milestone

Pioneering Success in Personalized Valve Study GrOwnValve GmbH just hit a big milestone that's caught my attention. Their first-in-human heart valve study wrapped up its six-month run with no prosthesis-related mishaps. Yeah, zero misfires. For five whole patients who've been through the wringer, things held steady. This Berlin startup’s got guts, testing tech that...

Pizza & Hope: Little Caesars Serves WV Communities

Rolling Out Dough and Kindness in West Virginia In a world that's more uncertain than a penny stock, here comes a story that'll warm even the coldest heart: Little Caesars is sending their Love Kitchen into West Virginia, aiming to serve piping hot pizza to about 8,000 folks in need. Fueled by the efforts of local franchisee Vicki Dunn-Marshall and her team, they're...

Blue Moon Metals Gears Up for Springer Mine Revamp

Getting Set for a Big Move Blue Moon Metals Inc. isn't sitting around with its thumbs in its pockets. The company has made some strides with their Springer Tungsten Mine project in Imlay, Nevada. Let's break down what these folks are up to. Refurbished Up for the Fast Track The rock mover here is the refurbishment of the Springer processing plant. You don't just snap your...

HDD vs SSD: EaseUS Report Shows Alarming Disk Health Trends

Disks Under the Microscope: Key Insights from 2026 Report Well, here's a data nugget that'll make you rethink your storage options: EaseUS Software dropped a disk health bombshell with their 2026 report, putting HDDs in the hot seat. Turns out, HDDs are about as trustworthy as a flaky friend, clocking in at 20 times more caution or bad health ratings compared to their...

Gentex Faces Investigation as Shares Tumble 7%

Investigating Gentex's Financial Setback Gentex Corporation, ticker NASDAQ:GNTX, is caught in a bit of a blizzard right now. Their shares took a nosedive, down 7%, after some messy numbers came out in their third-quarter report—tariffs and the kind of pricing pressure that makes grown investors wince. If you threw your chips in on Gentex and got burned, the lawyers are...

Ernesta Expands Southeast Reach with Atlanta Showroom

Ernesta's Southeast Play: The Atlanta Showroom Here's something to turn heads in the world of custom home design—Ernesta has just set up shop in Atlanta, a move that speaks volumes about their ambitions in the Southeast market. This isn't just about selling a few more rugs; it's a calculated step into a region ripe with design potential and a hunger for bespoke home...

Parloa's AI Agents Boost SAP Customer Experience

AI Meets SAP in Customer Experience Revolution Alright, let's cut through the tech chatter. Parloa’s Agent Management Platform has hitched its wagon to SAP as a spiffy Solution Extension. This isn't just tech fluff—it’s a big step for scratching that CX itch companies have. By merging Parloa's AI magic with SAP's existing mojo, businesses get a toolset to enhance...

Innventure Faces Legal Scrutiny Over DarkNX Debacle

Innventure’s Market Tumult: Unraveling the Drama Talk about a mess. Innventure Inc. (NASDAQ: INV) investors are likely feeling a sting sharper than a bee that's lost its hive after a painful 55% stock crash back in August 2026. The culprit? A scuttled project involving a shadowy partner, DarkNX, and a lot of questions about who knew what and when. A Puzzling...

Honeywell Aerospace Faces Lawsuit After Stock Tumbles 23%

Honeywell's Bumpy Ride Rattles Investors Something's brewing over at Honeywell Aerospace, Inc. (NASDAQ:HONA) and it's not your regular cup of joe. Investors, brace yourselves, because a securities fraud class action lawsuit is stacking up against them. With shares plummeting 23.16% in a whirlwind of a market day, it's kind of hard not to get a little riled up, isn't it?...